Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Metarka 25mg Tablet ER

Prescription Icon
Prescription Required

Marketer

Arkamed Pharmaa

Salt Composition

Metoprolol Succinate (25mg)

Overview Metarka 25mg Tablet ER

Cardiobeta 25mg Extended-Release Tablets are classified as beta-adrenergic blockers. This medication treats hypertension (high blood pressure), angina pectoris (chest pain from heart disease), and cardiac arrhythmias (irregular heartbeats). It's also used to help prevent migraines, recurrent heart attacks, and stroke. Cardiobeta 25mg ER may be administered independently or in conjunction with other therapies. Dosage and frequency are tailored to your specific condition and its severity. It can be taken with or without food, but consistent daily timing is crucial for optimal efficacy. Full therapeutic effects may take several weeks to manifest, and continuous use may be necessary. Discontinuing treatment, even with symptom improvement, can exacerbate your underlying condition. Common side effects, often mild and transient, include fatigue, cephalgia (headache), depression, diarrhea, skin rash, bradycardia (slow heart rate), dizziness, and nausea. Less frequently, shortness of breath or hypotension (low blood pressure) may occur. To minimize adverse reactions, your physician will likely initiate treatment with a low dose, gradually increasing it as tolerated. Report any persistent or bothersome side effects to your doctor. Prior to commencing treatment, inform your doctor of any liver impairment. This medication may be unsuitable for individuals with bradycardia, severe peripheral vascular disease, severe congestive heart failure, or hypotension. Pregnant or lactating women should seek medical counsel before use. Always consult your doctor to determine suitability and monitor your blood pressure regularly to assess treatment effectiveness. Alcohol consumption should be limited due to potential exacerbation of side effects.

Primary Ingredients of Metarka 25mg Tablet ER

No text was provided to rewrite.

Uses of Metarka 25mg Tablet ER

Managing angina pectoris (chest pain from heart conditions)|Correcting cardiac arrhythmias|Averting myocardial infarction|Controlling hypertension (elevated blood pressure)|Preventing migraine headaches

Major Benefits of Metarka 25mg Tablet ER:

Administer Metarka 25mg Extended-Release Tablets precisely as prescribed by your physician, both in terms of dosage and treatment length. The tablet should be swallowed whole; avoid chewing, crushing, or fracturing it. This medication can be ingested with or without food, though consistent timing is recommended. To maximize effectiveness, it's advisable to avoid consumption alongside meals high in fat, including those containing olive oil, nuts (particularly Brazil nuts), dark chocolate, butter, and red meat.

Common Side effects of Metarka 25mg Tablet ER:

  • Tiredness
  • Dizziness
  • Depression
  • Breathlessness
  • Headache
  • Slow heart rate
  • Nausea
  • Rash
  • Diarrhea
  • Hypotension (low blood pressure)

How to use Metarka 25mg Tablet ER:

Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Metarka 25mg Extended-Release Tablets can be consumed with or without food, although consistent timing is recommended. High-fat foods, including olive oil, nuts (especially Brazil nuts), dark chocolate, butter, and red meat, should be avoided when taking Metarka 25mg Extended-Release Tablets.

How Metarka 25mg Tablet ER works:

Cardio-selective extended-release Metarka 25mg tablets reduce cardiac workload. This is achieved by decreasing heart rate and improving the efficiency of blood circulation.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concurrent alcohol use with Metarka 25mg Extended-Release Tablets is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Metarka 25mg tablets might pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible dangers prior to prescription. Seek medical advice.

Breast feedingBreast feedingSAFE IF PRESCRIBED

Extended-release Metarka 25mg tablets are likely safe for breastfeeding mothers. Available evidence from human studies indicates minimal risk to the infant.

DrivingDrivingUNSAFE

Extended-release Metarka 25mg tablets can cause drowsiness, blurred vision, and dizziness. Driving should be avoided if these side effects manifest.

KidneyKidneySAFE IF PRESCRIBED

Extended-release Metarka 25mg tablets are considered safe for use in individuals with kidney impairment. No alteration of the Metarka 25mg extended-release tablet dosage is necessary.

LiverLiverCAUTION

Individuals with hepatic impairment should use Metarka 25mg Extended-Release tablets cautiously. Dosage modification of Metarka 25mg Extended-Release tablets may be necessary. Physician consultation is recommended.

What if you forget to take Metarka 25mg Tablet ER :

Should you forget to take a Metarka 25mg Extended-Release Tablet, administer it immediately upon remembrance. Nevertheless, if your next scheduled dose is imminent, omit the missed tablet and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Metarka 25mg Tablet ER

LabelValue
Type of Compound Ethyl alcohol and phenolic compounds
Potential for Dependence None.
Type of Medication HEART

FAQs on Metarka 25mg Tablet ER

Individual responses to Metarka 25mg Extended-Release tablets vary. Onset typically occurs within 15 minutes, though it may take up to two hours in some individuals. The therapeutic effect is gradual, with peak efficacy usually achieved within a week. Lack of immediate noticeable improvement is not cause for alarm; sustained use is necessary to realize the drug's full benefits.
Extended-release Metarka 25mg tablets are generally well-tolerated when administered according to a physician's instructions. However, abrupt cessation of this medication poses significant risks. Sudden discontinuation may trigger a rapid increase in heart rate and disrupt cardiac function, potentially posing severe danger to individuals with heart failure and potentially resulting in myocardial infarction in some cases. Therefore, discontinue this medication only under medical supervision and adhere to the prescribed treatment course.
Metarka 25mg Extended-Release tablets are classified as beta-blockers. While individual responses differ, these medications can sometimes modify sleep patterns and cause sleep disruption in some users. Conversely, they may improve sleep quality in individuals experiencing elevated heart rate and anxiety by reducing cardiac and nervous system activity. Consult your physician regarding any sleep-related issues.
Avoid alcohol consumption following ingestion of a 25mg extended-release Metarka tablet. Alcohol can potentiate the hypotensive effects of this medication, potentially causing dangerously low blood pressure.
Metarka 25mg Tablet ER
36
MRP 42
14% off